Key Highlights

  • Glaukos shares are up 32.89% at $241.10 on Thursday, October 29, 2026, the largest advance among the five.
  • Glaukos third-quarter net sales climbed 58% to $211.0 million, and its 2026 guidance moved up to $775 million to $785 million.
  • Crocs lifted full-year adjusted EPS guidance to $14.45 to $14.65 from $13.70 to $14.00.
  • Insmed revenue grew 268% to $524.4 million, with Brinsupri sales contributing $400.1 million.
  • FTAI Aviation unveiled a $500.0 million accelerated share repurchase, while Boot Barn added a $400 million authorization.

Which Stocks Above $100 Are Climbing After Earnings on October 29?

Five stocks priced above $100 are trading higher on Thursday, October 29, 2026, and each follows an earnings report. Glaukos (NYSE:GKOS) is up 32.89% at $241.10, Crocs (NASDAQ:CROX) is up 25.66% at $150.41, Insmed (NASDAQ:INSM) is up 16.30% at $112.79, FTAI Aviation (NASDAQ:FTAI) is up 13.52% at $189.73 and Boot Barn (NYSE:BOOT) is up 13.50% at $128.59.

The order follows the size of the percentage gain given in each company's own article, all taken on the same day. It does not track raw growth, since the fastest sales growth and the largest share move do not coincide for every name.

1. Glaukos: What Is Behind the 32.89% Surge After Third-Quarter Results?

Glaukos is an ophthalmic company based in Aliso Viejo, California, focused on glaucoma, corneal disorders and retinal disease. On Wednesday, October 28 it said third-quarter net sales grew 58% to $211.0 million, with Corneal Health up 154% to $59.0 million and U.S. Glaucoma up 47% to $118.6 million. The implied prior close is about $181.40 (calculated).

GAAP net income came to $2.0 million, compared with a $16.2 million loss a year earlier, and 2026 net sales guidance moved to $775 million to $785 million from $680 million to $700 million. The company also gave a preliminary 2027 net sales figure of $1 billion. Cash, short-term investments and restricted cash totaled $339.8 million at September 30, with no debt reported. Non-GAAP net income was $28.5 million, or $0.47 per share, and the release offered no margin guidance or named trial readouts.

2. Crocs: How Did a Higher Full-Year Guide Fuel the 25.66% Rally?

Crocs posted third-quarter revenue of $1,043 million, up 4.6%, and adjusted diluted EPS of $3.69 versus $2.92 a year ago. HEYDUDE grew again, with revenue up 6.1% to $170 million. The implied prior close is about $119.69 (calculated).

GAAP gross margin of 66.2% includes a $64.1 million non-recurring gain from tariff refunds, and adjusted gross margin was 60.3%. Full-year adjusted EPS guidance now sits at $14.45 to $14.65, and about 2.0 million shares were repurchased for $250.0 million during the quarter. The Crocs Brand produced $873 million, up 4.4%, as international revenue rose 11.8% to $434 million and North America slipped 2.1%. Free cash flow reached $275.5 million, and fourth-quarter adjusted EPS is guided to $3.25 to $3.45.

3. Insmed: Do Near-$400 Million Brinsupri Sales Account for the 16.30% Advance?

Insmed markets Brinsupri, approved for non-cystic fibrosis bronchiectasis, along with Arikayce for a chronic lung infection. Third-quarter revenue grew 268% to $524.4 million, made up of $400.1 million from Brinsupri and $124.4 million from Arikayce, which was up 9%.

The 2026 Brinsupri guide is now $1.35 billion to $1.40 billion, compared with $1.25 billion to $1.40 billion before. The net loss narrowed to $100.3 million from $370.0 million, and 219.3 million shares outstanding imply a market value near $24.7 billion (calculated). Cash, equivalents and marketable securities were about $1,146.6 million at September 30, 2026. Japan approved Brinsupri in August 2026 with a launch in October, and Arikayce guidance shifted to $460 million to $470 million.

4. FTAI Aviation: Beyond the $500 Million Buyback, What Powered the 13.52% Gain?

FTAI Aviation said third-quarter revenue was $977.7 million, against $667.1 million before, and net income attributable to shareholders was $149.1 million, or $1.43 per diluted share. Aerospace Products revenue grew 76% to $910.0 million, while Aviation Leasing adjusted EBITDA dropped to $104.0 million from $134.4 million. The implied prior close is about $167.13 (calculated).

The $500.0 million accelerated repurchase is roughly 2.6% of a market value near $19.4 billion (calculated), and it is expected to finish in the fourth quarter. An engine exchange agreement with United Airlines (NASDAQ:UAL) was announced on October 8. Nine-month revenue totaled $2,761.4 million versus $1,845.4 million, and on October 27 the board raised total repurchase authorization to $1.0 billion. At September 30, cash was $385.6 million and long-term debt was $3,455.5 million.

5. Boot Barn: Did Repurchases and a Refreshed Outlook Outweigh Muted Same Store Sales?

Boot Barn, an Irvine, California retailer of western and work footwear, said fiscal second-quarter net sales grew 15.1% to $581.8 million on Wednesday, October 28. Same store sales gained 1.4%, and diluted EPS was $1.73. The implied prior close is about $113.30 (calculated).

The board approved a further $400 million of repurchases on October 21. Fiscal 2027 diluted EPS is now guided to $8.72 to $9.00, with roughly $0.45 of that linked to tariff refunds. Operating income was $70.2 million, a 12.1% margin, and net income rose to $52.5 million from $42.2 million. As of the release date the company ran 594 stores across 49 states, and plans for fiscal 2027 include 75 to 80 new stores.

Top 5 Earnings Gainers Side by Side: How Do the Moves, Prices and Growth Compare?

Glaukos' gain exceeds Crocs' by 7.23 percentage points and Boot Barn's by 19.39 points, while FTAI Aviation and Boot Barn sit just 0.02 points apart (all calculated). Dollar moves from the implied prior closes are about $59.70 at Glaukos, $30.72 at Crocs, $22.60 at FTAI Aviation and $15.29 at Boot Barn (calculated).

Reported revenue growth spans 4.6% at Crocs to 268% at Insmed, and FTAI Aviation's revenue grew about 46.6% (calculated). Crocs had the slowest growth yet the second-largest move, helped by a higher guide. Four of the five raised or updated their outlooks, while FTAI Aviation reaffirmed its 2026 and 2027 adjusted EBITDA guidance.

What to Watch Next: The Arikayce Decision, the Holiday Quarter and Fourth-Quarter Guides

The FDA Priority Review target date for Insmed's Arikayce supplemental application is January 28, 2027. Boot Barn's third quarter closes December 26, 2026, with diluted EPS guided to $3.03 to $3.19, and Crocs has set fourth-quarter revenue growth at 7% to 9% with adjusted EPS of $3.25 to $3.45.

FTAI Aviation's $0.50 per share dividend has a November 10 record date and a November 23 payment date, and its repurchase should wrap up in the fourth quarter. Glaukos' fourth-quarter results will show how sales are tracking toward the raised $775 million to $785 million range.